Filter
2083
Filtered Results: 2083
Text search:
drug
market
Featured
Recommendations
169
New Publications
622
Language
Document type
No document type
1241
Studies & Reports
352
Guidelines
256
Strategic & Response Plan
89
Manuals
78
Fact sheets
30
Training Material
18
Situation Updates
8
Resource Platforms
7
Infographics
2
App
1
Online Courses
1
Countries / Regions
India
116
Global
77
Kenya
72
Ethiopia
68
Uganda
68
Nigeria
50
Western and Central Europe
47
Bangladesh
43
Liberia
42
Ghana
42
Myanmar / Burma
39
Sierra Leone
36
Malawi
36
Nepal
35
Tanzania
31
Zambia
30
South Africa
30
Africa
30
Rwanda
28
Zimbabwe
24
Philippines
23
Ukraine
22
South–East Asia Region
21
Latin America and the Carribbean
20
Cambodia
19
Namibia
19
Congo, Democratic Republic of
17
Lesotho
16
Asia
15
Eastern Europe
15
Botswana
14
Indonesia
12
Russia
12
Senegal
11
Syria
11
Brazil
10
Venezuela
10
Burkina Faso
9
Mozambique
9
Guinea
8
Cameroon
7
Thailand
7
Albania
7
USA
6
Haiti
6
Eswatini/ Swaziland
6
East and Southern Africa
6
Eastern Europe and Central Asia
6
China
5
Sudan
5
West and Central Africa
5
Middle East and North Africa
5
Vietnam
5
South Sudan
4
Germany
4
Colombia
4
Sri Lanka
4
Laos
4
Georgia
4
Lebanon
3
Benin
3
Peru
3
North Macedonia
3
Libya
3
Mexico
3
Western Pacific Region
3
Timor Leste/ East Timor
3
Tajikistan
3
Moldova
3
Somalia
2
Pakistan
2
Iraq
2
Jordan
2
Central African Republic
2
Argentina
2
Hungary
2
Chile
2
Bhutan
2
Poland
2
Iran
2
Kyrgyzstan
2
Morocco
1
Afghanistan
1
Turkey
1
Papua New Guinea
1
Serbia
1
Bolivia
1
Madagascar
1
Yemen
1
Paraguay
1
Fiji
1
Palestine
1
North Korea
1
Italy
1
Canada
1
Qatar
1
Bulgaria
1
Estonia
1
Kazakhstan
1
North America
1
Turkmenistan
1
Jamaica
1
Denmark
1
Maldives
1
Mauritius
1
Tunisia
1
Norway
1
Portugal
1
Authors & Publishers
Publication Years
Category
Countries
884
Clinical Guidelines
151
Public Health
110
Women & Child Health
61
Key Resources
48
Pharmacy & Technologies
43
Capacity Building
17
Toolboxes
HIV
210
Mental Health
180
AMR
159
TB
126
Pharmacy
119
COVID-19
93
NCDs
44
NTDs
39
Planetary Health
32
Ebola
30
Conflict
28
Rapid Response
27
Global Health Education
26
Refugee
24
Caregiver
23
Disability
22
Health Financing Toolbox
21
Cholera
9
Natural Hazards
8
Polio
4
Specific Hazards
4
Social Ethics
4
Zika
1
Health Financing
1
Countries, partners, and donors are committed to
the global elimination of blinding trachoma by 2020.
Achieving this public health milestone requires more
than funding; it requires health personnel with the
right mix of skills, and well supported and managed
health systems. Mass ... administration (MDA)
with Zithromax®, the Pfizer, Inc. donated antibiotic,
is a key component of the SAFE strategy, endorsed
by the World Health Organization. There is growing
recognition that improving all aspects of MDA, from
planning to training, recording to reporting, and
receipt of drug to distribution (the supply chain), will
be necessary if MDA programmes are going to reduce
the community burden of Chlamydia trachomatis, and
eliminate trachoma as a cause of blindness by 2020.
2nd revised edition. Accessed Apri. 17, 2019
Prevention strategies based on scientific evidence working with families, schools, and communities can ensure that children and youth, especially the most marginalized and poor, grow and stay healthy and safe into adulthood and old age. For every dollar ...
PLOS ONE | DOI:10.1371/journal.pone.0144057 December 14, 2015
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of...
UN, international agencies and experts released a groundbreaking report demanding immediate, coordinated and ambitious action to avert a potentially disastrous drug-resistance crisis.
If no action is taken - warns the UN Ad hoc Interagency Coordin...
Available in English, French, Spanish, Russian, Chinese, Arabic and Portugues
In Vietnam, most of the examination and treatment facilities are facing with of spread of bacteria resistant to many antibiotics. The level and speed of drug resistance are increasing, at alarming level. The burden of ... resistance is increasing due to the increasing cost of treatment, prolonged treatment,. That will affect patients’ health, community and social development. In the future, many
nations will be able to face the possibility of having no effective drugs to treat infectious diseases if they do not make appropriate interventions.
Policy brief. July 2020
The Strategy to respond to antimalarial drug resistance in Africa is a technical and advocacy document, grounded in the best available evidence to date and aimed at minimizing the threat and impact of antimalarial ... resistance of Plasmodium falciparum parasites in Africa. Its objectives are to: i) improve the detection of resistance to ensure a timely response; ii) delay the emergence of resistance to artemisinin and artemisinin-based combination therapy (ACT) partner drugs; and iii) limit the selection and spread of resistant parasites where resistance has been confirmed.
WHO Team
Global Malaria Programme
Editors
World Health Organization
Number of pages
87
Reference numbers
ISBN: 978 92 4 006026 5
Copyright
The emergence of multifrug-resistant malaria in the Greater Mekong Subregion (GMS) has been identified as an emergency issue that may have catastrophic consequences on the future of malaria elimination in the GMS as well as globally. In recognition of the need for a cohesive regional response,...
Q 6. Does the provision of sterile injection equipment to injecting drug users reduce injecting related harm? Is advice on ways to reduce drug related harm safe and effective, using an outreach mode...
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically ...
